Trial Profile
Exploratory trial of APR-246 in patients with solid and hematological tumors
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2016
Price :
$35
*
At a glance
- Drugs Eprenetapopt (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Sponsors Aprea
- 11 Mar 2016 New trial record